MK591

• CAT Number: I001789
• CAS Number: 147030-01-1
• Molecular Formula: C34H34ClN2NaO3S
• Molecular Weight: 609.15
• Purity: ≥95%
• Target: FLAP
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: sodium;3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate
• InChI: InChI=1S/C34H35ClN2O3S.Na/c1-33(2,3)41-31-27-18-26(40-21-25-15-12-23-8-6-7-9-28(23)36-25)16-17-29(27)37(20-22-10-13-24(35)14-11-22)30(31)19-34(4,5)32(38)39;/h6-18H,19-21H2,1-5H3,(H,38,39);/q;+1/p-1
• InChIKey: YPURUCMVRRNPHJ-UHFFFAOYSA-M
• SMILES: CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)[O-].[Na+]

Quiflapon sodium (MK-591 sodium)（Cat No.:I001789） is a selective and specific inhibitor of 5-lipoxygenase-activating protein (FLAP), an enzyme involved in leukotriene biosynthesis. By inhibiting FLAP, Quiflapon sodium effectively suppresses the production of leukotrienes, which are inflammatory mediators. This compound demonstrates potent activity and can be administered orally. Additionally, Quiflapon sodium has been shown to induce apoptosis, a form of programmed cell death, potentially contributing to its therapeutic effects.

Reference

[1]. Brideau C, Chan C, Charleson S et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1992 Jun;70(6):799-807.
[2]. Mendis C, Campbell K, Das R et al. Effect of 5-lipoxygenase inhibitor MK591 on early molecular and signaling events induced by staphylococcal enterotoxin B in human peripheral blood mononuclear cells. FEBS J. 2008 Jun;275(12):3088-98.
[3]. Sarveswaran S, Myers CE, Ghosh J. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3/’-kinase. Cancer Lett. 2010 May 28;291(2):167-76.
[4]. Park MS, Sohn MH, Kim KE et al. 5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner. Lung. 2011 Feb;189(1):43-50.
[5]. Chu J, Praticò D. Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer/’s disease mouse model. J Neuroinflammation. 2012 Jun 14;9:127.